Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) reported Q3 2025 net sales of $533 million (+6% at actual rates) and adjusted diluted EPS of $0.61, above its outlook. The company raised its FY2025 adjusted diluted EPS target to about $2.38 CER (from $2.35) and reaffirmed net sales growth of about 4–5% CER (core sales ~5–6% CER). Q3 adjusted operating income margin remained strong near 29.6% and operating cash flow was $165 million.

QIAGEN announced the acquisition of Parse Biosciences to enter the single-cell market and approved a $500 million synthetic share repurchase to be completed in January 2026. The CEO will transition after a successor is appointed.

QIAGEN (NYSE: QGEN) will acquire Parse Biosciences to expand its Sample technologies into scalable single-cell solutions. QIAGEN will pay an upfront $225 million in cash, with up to $55 million in milestone payments; the deal is expected to close in December 2025. Parse brings Evercode instrument-free chemistry, the Tahoe-100M dataset (>100 million cells), GigaLab capacity of 2.5 billion cells/year, and use in >3,000 labs. Parse is expected to add ~$40 million revenue in 2026 (~2 percentage points growth) and to be dilutive ~$0.04 EPS in 2026, turning accretive in 2028.

QIAGEN (NYSE: QGEN) launched the EZ2 DNA Investigator Sep&Prep Kit for automated sexual assault sample processing, announced ahead of ISHI 2025 (Nov 3–6, 2025).

The kit runs on EZ2 Connect Fx, can process up to 24 samples in parallel, and delivers sperm-derived DNA ready for downstream profiling or NGS in under 2.5 hours. It uses a novel lysis buffer plus proprietary bead technology to improve sperm recovery and reduce victim DNA carryover while cutting hands-on time and variability versus manual differential extraction.

QIAGEN will showcase the kit and its forensics portfolio at ISHI 2025 in Palm Beach, Florida.

QIAGEN (NYSE: QGEN) announced the 4,000th placement of its QIAcube Connect instrument, part of nearly 13,000 cumulative QIAcube family placements and more than 29,900 cumulative QIAGEN Sample technology placements since 2019. QIAcube Connect supports over 80 kits, >140 standard protocols and >3,000 custom protocols, and adds connectivity, remote monitoring, automated decontamination and QIAsphere integration.

QIAGEN plans three new automation launches in 2025–2026: QIAsymphony Connect (up to 96 samples/run), QIAsprint (up to 192 samples/run) and QIAmini (compact benchtop).

QIAGEN (NYSE: QGEN) will release its Q3 2025 results on Tuesday, November 4, 2025 shortly after 22:05 Frankfurt / 21:05 London / 16:05 New York. A conference call will follow on Wednesday, November 5, 2025 at 15:30 Frankfurt / 14:30 London / 09:30 New York.

Investors can join via three options: register for callback, dial in by phone (U.S. +1 929 477 0402; UK +44 (0)330 165 3655; GER +49 (0)69 6610 2480) using Conference ID 3763132, or access the live audio webcast. A conference replay will be available at the provided webcast link. For IR inquiries contact IR@qiagen.com.

QIAGEN (NYSE: QGEN) has achieved CE-IVDR certification for its complete QIAstat-Dx syndromic testing portfolio, including an enhanced Meningitis/Encephalitis (ME) Panel featuring 16 clinically relevant targets. The expanded ME Panel, launching in September 2025, uniquely includes cytomegalovirus (CMV) and exclusive detection of Streptococcus pyogenes.

The QIAstat-Dx system, with over 4,600 installations globally, delivers comprehensive results in about an hour and is available in two formats: the standard Analyzer version and the higher-capacity Rise version capable of 160 tests per day. The platform offers CE-IVDR certified panels for respiratory, gastrointestinal, and CNS infections, featuring a simplified one-step workflow requiring minimal hands-on time.

QIAGEN (NYSE: QGEN) has received FDA clearance for its QIAstat-Dx Rise, an enhanced version of its automated syndromic testing system. The new system offers significantly higher throughput, capable of processing up to 160 samples per day across eight analytical modules, including 16 batch samples and two urgent slots per run.

The system features automated loading and unloading of cartridges, priority handling of urgent samples, and minimal hands-on time, delivering results in about one hour. Initially launching with Respiratory Panel Plus and Respiratory Panel Mini, QIAGEN plans to expand the test menu with gastrointestinal panels in the coming months. The QIAstat-Dx platform has already achieved significant market penetration with over 4,600 instruments placed globally through H1 2025 across more than 100 countries.

QIAGEN (NYSE: QGEN) has announced the final terms of its new senior, unsecured net share settled convertible bonds due 2032. The company is issuing $750 million in convertible bonds with an initial conversion price of $64.6338 per share, representing a 40% premium above the reference share price of $46.1670.

Upon conversion, bondholders will receive cash equal to the bonds' par value plus shares equivalent to the underlying value. The settlement date is set for September 4, 2025, with trading to commence on Frankfurt's Open Market. The proceeds will be used for general corporate purposes and debt refinancing. QIAGEN has agreed to a 90-day lock-up period for similar securities.

QIAGEN (NYSE: QGEN) has announced the successful placement of new senior, unsecured net share settled convertible bonds due 2032. The offering totals $750 million in aggregate principal amount with a 2.0% annual coupon payable semi-annually.

The convertible bonds will feature an initial conversion price set at a 40% premium over the reference share price, which will be determined based on the volume weighted average price of QIAGEN shares on the NYSE on August 28, 2025. The company has agreed to a 90-day lock-up period following the settlement date, during which it won't sell similar securities or shares, subject to certain exceptions.